1. AB0576 Evaluation of surfactant protein-D and KL-6 as potential pulmonary safety biomarkers during mavrilimumab treatment. (23rd January 2014) Authors: Spitz, S.; Wilkins, D.; Esfandiari, E.; Godwood, A.; Roskos, L.; Ryan, P.; Magrini, F. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0182 Pharmacokinetics and immunogenicity of mavrilimumab administered subcutaneously in subjects with rheumatoid arthritis. (23rd January 2014) Authors: Wu, C.-Y.; Chen, X.; Lu, H.; Esfandiari, E.; Magrini, F.; Godwood, A.; Ryan, P.; Kane, C.; Roskos, L.; Wang, B. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0210 First-in-Patient Study of Namilumab, an Anti-GM-CSF Monoclonal Antibody, in Active Rheumatoid Arthritis: Results of the Priora Phase IB Study. (9th June 2015) Authors: Huizinga, T.W.J.; Batalov, A.; Yablanski, K.; Stoilov, R.; Lloyd, E.; Wagner, T.; Saurigny, D.; Souberbielle, B.; Esfandiari, E. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SAT0226 A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-rising dose study of the btk inhibitor tak-020 in healthy volunteers. (12th June 2018) Authors: Esfandiari, E.; Gevorkyan, H.; Faessel, H.; Zhao, Z.; Hanna, K.; Smithson, G.; Wagner, J.; Fedyk, E. R.; Mclean, L. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 974 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗